clinical trial · NCT06497127
A Study in Patients With Mixed Dyslipidemia
Shanghai Argo Biopharmaceutical Co., Ltd.·phase2·active not recruiting·n = 145
Mixed DyslipidemiaBW-00112
brief summary
A Phase 2 in Patients With Mixed Dyslipidemia
started
Feb 28, 2024
primary completion
Jun 30, 2026
completion
Mar 30, 2028
last updated
Jan 13, 2026
detailed description
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Subcutaneously Administered BW-00112 in Patients with Mixed Dyslipidemia
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Subcutaneously Administered BW-00112 in Patients With Mixed Dyslipidemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol